FAQ : ADR Reporting by Healthcare Professionals

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
1) What is the scope of ADR Monitoring?
Reporters are encouraged to report any suspicious adverse event, especially on:

- Newly registered drugs

- Reactions encountered with generic products which are not commonly associated with the equivalent market leader product

- Off-label indications

- Doses differing from the recommended doses
2) What should not be reported?
3) What to report?
4) How to report?
5) Basic principles of efficient reporting.
6) Is there any guideline available for ADR reporting and monitoring?

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Wednesday 20 February 2019, 11:38:11.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language